Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Reprogramming Method Makes Better Stem Cells

July 2, 2014 1:07 pm | News | Comments

A team of researchers from the University of California, San Diego School of Medicine, Oregon Health & Science University and Salk Institute for Biological Studies has shown for the first time that stem cells created using different methods produce differing cells. Read more...

TOPICS:

RNA Reprogramming Technology for Generates Virus-free iPSCs

July 2, 2014 1:03 pm | EMD Millipore | Product Releases | Comments

Simplicon RNA Reprogramming Technology from EMD Millipore uses synthetic self-replicating RNA to create large numbers of human induced pluripotent stem cells (iPSCs) using a single transfection step. Read more...

TOPICS:

Safe, Efficient Concentration of Biological Samples

July 2, 2014 11:04 am | Product Releases | Comments

The miVac DNA is a compact concentrator from Genevac capable of safely and efficiently removing water and organic solvents from biological samples in a variety of formats including tubes, microplates and vials. Read more...

TOPICS:
Advertisement

Pfizer Receives Kosher Certification for Gaucher Disease Drug

July 2, 2014 10:55 am | News | Comments

Pfizer Inc. announced that the Orthodox Union has granted kosher certification to Elelyso (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. Read more...

TOPICS:

Isis Earns $1M from GSK for Advancing Hep B Program

July 2, 2014 10:49 am | News | Comments

Isis Pharmaceuticals Inc. announced that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus, a serious health problem that can lead to significant and potentially fatal health conditions. Read more...

TOPICS:

Common Element of Ancient Origin Controls Na, Ca Cellular Gates

July 2, 2014 10:43 am | News | Comments

Researchers at Johns Hopkins have spotted a strong family trait in two distant relatives: The channels that permit entry of sodium and calcium ions into cells - both of which are critical to life - turn out to share similar means for regulating ion intake, they say. Read more...

TOPICS:

Lung Cancer Alliance Commends NCI for SCLC Scientific Framework

July 2, 2014 10:32 am | News | Comments

The National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. Read more...

TOPICS:

Roche Buying Seragon for Up to $1.7B

July 2, 2014 10:13 am | News | Comments

Roche Holding AG - the Basel, Switzerland-based pharmaceutical giant - said its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals Inc. for up to $1.725 billion in cash and contingency payments. Read more...

TOPICS:
Advertisement

OncoGenex Opens Enrollment for Lung Cancer Trial

July 2, 2014 8:30 am | News | Comments

OncoGenex announced initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer. Read more...      

TOPICS:

Approach IDs Mutations as Targets for Melanoma Immunotherapy

July 2, 2014 8:30 am | News | Comments

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. Read more...

TOPICS:

Quark Completes Trial of siRNA Compound in Kidney Transplant Patients

July 2, 2014 8:30 am | News | Comments

Quark Pharmaceuticals reported completion of a randomized, placebo-controlled multicenter Phase 2 trial of QPI-1002 for the prophylaxis of delayed graft function in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. Read more...

TOPICS:

Sanofi Pasteur, CureVac to Develop mRNA-based Prophylactic Vaccine

July 2, 2014 8:30 am | News | Comments

CureVac and Sanofi Pasteur S.A. have executed an exclusive license agreement to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. Read more...                       

TOPICS:

Agenus Glioblastoma Vaccine Extends Survival in Phase 2

July 2, 2014 8:30 am | News | Comments

Agenus announced Phase 2 study results showing that patients with newly diagnosed glioblastoma multiforme who received Prophage autologous cancer vaccine, added to the standard of care treatment, lived nearly twice as long as expected. Read more...

TOPICS:

UMD, GBSI Partner to Advance Antibody Standards

July 1, 2014 2:22 pm | News | Comments

The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. Read more...

TOPICS:

NIH Adds New Clinical Sites in Undiagnosed Diseases Network

July 1, 2014 1:57 pm | News | Comments

The National Institutes of Health has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them. Read more...        

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading